Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a severe decline of memory performance. A widely studied AD mouse model is the APPswe/PSEN1DE9 (APP/PS1) strain, as mice exhibit amyloid plaques as well as impaired memory capacities. To test whether restoring synaptic plasticity and decreasing β-amyloid load by Parkin could represent a potential therapeutic target for AD, we crossed APP/PS1 transgenic mice with transgenic mice overexpressing the ubiquitin ligase Parkin and analyzed offspring properties. Overexpression of Parkin in APP/PS1 transgenic mice restored activity-dependent synaptic plasticityandrescuedbehavioral abnormalities. Moreover, overexpression of Park in was associated withdownregulation of APP protein expression, decreased β-amyloid load and reduced inflammation. Our data suggest that Parkin could be a promising target for AD therapy. © The Author 2013. Published by Oxford University Press. All rights reserved.
CITATION STYLE
Hong, X., Liu, J., Zhu, G., Zhuang, Y. H., Suo, H., Wang, P., … Huang, F. (2014). Parkin overexpression ameliorates hippocampal long-term potentiation and β-amyloid load in an Alzheimer’s disease mouse model. Human Molecular Genetics, 23(4), 1056–1072. https://doi.org/10.1093/hmg/ddt501
Mendeley helps you to discover research relevant for your work.